WO2003074033A1 - Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping - Google Patents
Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping Download PDFInfo
- Publication number
- WO2003074033A1 WO2003074033A1 PCT/HR2002/000018 HR0200018W WO03074033A1 WO 2003074033 A1 WO2003074033 A1 WO 2003074033A1 HR 0200018 W HR0200018 W HR 0200018W WO 03074033 A1 WO03074033 A1 WO 03074033A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- water
- tablets
- active agent
- component
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 238000009472 formulation Methods 0.000 title claims abstract description 39
- 238000013268 sustained release Methods 0.000 title claims abstract description 38
- 230000002829 reductive effect Effects 0.000 title claims abstract description 5
- 238000013270 controlled release Methods 0.000 title abstract description 15
- 230000002459 sustained effect Effects 0.000 title abstract description 5
- 239000007787 solid Substances 0.000 title description 8
- 238000012377 drug delivery Methods 0.000 title description 6
- 239000013543 active substance Substances 0.000 claims abstract description 65
- 239000000463 material Substances 0.000 claims abstract description 51
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims description 50
- 239000008187 granular material Substances 0.000 claims description 39
- 239000012730 sustained-release form Substances 0.000 claims description 33
- 239000002552 dosage form Substances 0.000 claims description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 229960001193 diclofenac sodium Drugs 0.000 claims description 12
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 12
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229960000620 ranitidine Drugs 0.000 claims description 10
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 10
- 229960001520 ranitidine hydrochloride Drugs 0.000 claims description 10
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 claims description 10
- 239000000454 talc Substances 0.000 claims description 10
- 229910052623 talc Inorganic materials 0.000 claims description 10
- 229960005461 torasemide Drugs 0.000 claims description 10
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 9
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 9
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims description 8
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000007909 solid dosage form Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 235000012631 food intake Nutrition 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000004150 EU approved colour Substances 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 abstract description 9
- 239000003814 drug Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 23
- 150000002632 lipids Chemical class 0.000 description 23
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 229960000074 biopharmaceutical Drugs 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000009506 drug dissolution testing Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 229940088679 drug related substance Drugs 0.000 description 9
- 230000002035 prolonged effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 239000007900 aqueous suspension Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003340 retarding agent Substances 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- -1 glycerine fatty acid esters Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229920003176 water-insoluble polymer Polymers 0.000 description 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003164 Eudragit® NE 40 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229960001495 pravastatin sodium Drugs 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960002416 venlafaxine hydrochloride Drugs 0.000 description 1
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- Present innovation is related to a sustained/controlled release formulation for solid pharmaceuticals, primarily designed for oral administration.
- the innovation is referred to a two-component system which ensures sustained release of the active substance, therefore administration of a single dosage unit once or twice daily.
- controlled/sustained release dosage forms allow the drug(s) to be released in optimum amounts, minimising unwanted side effects over a prolonged period, thus obviating the need for multiple administration.
- controlled/sustained release dosage forms have now become the state of the art in the area of drug delivery technology. Large number of drug delivery systems which would release a sufficient amount of drug(s) for the initial bioavai lability for faster action, followed by a controlled/sustained release for prolonged/continuous action over time have been described, e.g:
- Biopharmaceutics Classification Scheme categorises drug substances into four basic groups according to their solubility and capability to penetrate into plasma through the gastrointestinal wall (e.g. Dressman, J.B at al, Pharm. Res., 15(1) (1998) 11-22).
- Drug substances belonging to Class I are highly soluble and highly permeable.
- Drug substances belonging to Class II are poorly soluble and highly permeable.
- Drug substances belonging to Class III are highly soluble and poorly permeable, whereas substances belonging to Class IV are poorly soluble and poorly permeable drugs.
- An object of the present invention is to provide an oral controlled/sustained release formulation with minimised risk of dose dumping and side effects, or, at least, to provide the public with a useful choice, independently of the solubility and permeability of the drug substances.
- the present invention provides a solid controlled release oral dosage formulation, comprising two components wherein: a) the first component comprises a pharmaceutically active agent and a pharmaceutically acceptable, water-insoluble, water-permeable polymeric material; and b) the second component comprises a mixture of a pharmaceutically active agent and a hydrophobic material.
- the present invention provides a method of minimising dose dumping comprising administering to a patient in need thereof of a sustained release solid dosage formulation including two components wherein: a) the first component comprises a pharmaceutically active agent and a pharmaceutically acceptable, water-insoluble, water-permeable polymeric material; and b) the second component comprises a mixture of a pharmaceutically active agent and a hydrophobic material.
- the present invention provides a use, in the preparation of a medicament for sustained release of a pharmaceutically active agent in a patient in need thereof, of a sustained release solid dosage formulation including two components wherein: a) the first component comprises a pharmaceutically active agent and a pharmaceutically acceptable, water-insoluble, water-permeable polymeric material; and b) the second component comprises a mixture of a pharmaceutically active agent and a hydrophobic material.
- the present invention provides a use, in the preparation of a medicament with minimised dose dumping of a pharmaceutically active agent, in a patient in need thereof, of a sustained release solid dosage formulation including two components wherein: a) the first component comprises a pharmaceutically active agent and a pharmaceutically acceptable, water-insoluble, water-permeable polymeric material; and b) the second component comprises a mixture of a pharmaceutically active agent and a hydrophobic material.
- the present invention provides a process for the production of a sustained release solid dosage form, including the steps of: • providing a first component comprising a pharmaceutically active agent and a pharmaceutically acceptable water-insoluble, but water-permeable polymeric material; and combining the first component with
- a second component comprising a mixture of a pharmaceutically active agent and a hydrophobic material.
- the present invention provides a method for producing a dosage formulation with a desired sustained release profile in a dosage formulation comprising:
- a second component comprising a pharmaceutically active agent and a hydrophobic material, said pharmaceutically active agent and a hydrophobic material mixed in a predetermined ratio such that the combination of the first and second components, in use, result with a desired sustained release profile.
- Figure 1 is a graph depicting sustained release using a dosage formulation of the invention. It depicts controlling/sustaining the release rate by changing the amount of water-insoluble (but water-permeable) polymeric material. Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, diclofenac sodium contained in the dosage form is poorly soluble and highly permeable (Class II, according to Biopharmaceuticals Classification System).
- Figure 2 is a graph depicting sustained release using a dosage formulation of the invention.
- Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, diclofenac sodium, contained in the dosage form is poorly soluble and highly permeable (Class II, according to Biopharmaceuticals Classification System).
- Figure 3 is a graph depicting sustained release using a dosage formulation of the invention. It depicts controlling/sustaining the release rate by changing the amount of water-insoluble (but water-permeable) polymeric material and/or lipid/lipidic component. Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, diclofenac sodium, contained in the dosage form is poorly soluble and highly permeable (Class II, according to Biopharmaceuticals Classification System).
- Figure 4 is a graph depicting sustained release using a dosage formulation of the invention. It depicts influence of the water-soluble excipients in granules and/or water- insoluble excipients in the tablet blend. Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, diclofenac sodium, contained in the dosage form is poorly soluble and highly permeable (Class II, according to Biopharmaceuticals Classification System).
- Figure 5 is a graph depicting sustained release using a dosage formulation of the invention. It depicts controlling/sustaining the release rate by changing the amount of water-insoluble (but water-permeable) polymeric material. Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, torasemide, contained in the dosage form is highly soluble and highly permeable (Class I, according to Biopharmaceuticals Classification System).
- Figure 6 is a graph depicting sustained release using a dosage formulation of the invention. It depicts controlling/sustaining the release rate by changing the amount of lipid/lipidic component as an additional retarding agent. Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, torasemide, contained in the dosage form is highly soluble and highly permeable (Class I, according to Biopharmaceuticals Classification System).
- Figure 7 is a graph depicting sustained release using a dosage formulation of the invention. It depicts controlling/sustaining the release rate by changing the amount of water-insoluble (but water-permeable) polymeric material and/or lipid/lipidic component. Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, torasemide, contained in the dosage form is highly soluble and highly permeable (Class I, according to Biopharmaceuticals Classification System).
- Figure 8 is a graph depicting sustained release using a dosage formulation of the invention. It depicts controlling/sustaining the release rate by changing the amount of water-insoluble (but water-permeable) polymeric material. Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, ranitidine (in the form of ranitidine hydrochloride), contained in the dosage form is highly soluble and poorly permeable (Class III, according to Biopharmaceuticals Classification System).
- Figure 9 is a graph depicting sustained release using a dosage formulation of the invention.
- Figure 10 is a graph depicting sustained release using a dosage formulation of the invention. It depicts controlling/sustaining the release rate by changing the amount of water-insoluble (but water-permeable) polymeric material and/or lipid/lipidic component. Dissolution testing was carried out by using USP apparatus I at 150 rpm. For the first 30 minutes the release profile was tested in diluted hydrochloric acid (pH 2.5) and then in mixed phosphate buffer (pH 6.8) for 8 hours. The data represent mean values obtained from 6 tablets.
- the pharmaceutically active agent, ranitidine in the form of ranitidine hydrochloride
- contained in the dosage form is highly soluble and poorly permeable (Class III, according to Biopharmaceuticals Classification System).
- the present invention relates to a novel solid sustained/controlled release oral dosage formulation.
- the formulation of the invention comprises a two-component system.
- the first component comprises an active pharmaceutical agent in combination with a water- insoluble, but water-permeable polymer.
- the first component is preferably in the form of granules and is capable of sustaining the release of the active agent over a prolonged period of time, depending on the amount of polymer, either if the shape of the dosage form remains intact or even if it is disintegrated into small pieces.
- the water-insoluble, but water-permeable polymeric material comprises one or more methacrylic acid copolymers, ethylcellulose or mixture thereof and others with similar properties.
- the water-insoluble, but water-permeable polymeric material is presented in an amount within the range of from about 2-90% (w/w) and/or in the proportion to the active substance from (1 : 10) to (10: 1).
- the second component of the system contains an active pharmaceutical agent, untreated with the water-insoluble polymer, and available for substantially immediate release, depending on the physico-chemical properties of the active agent.
- the second component of the formulation also contains a hydrophobic, preferably a lipid or lipidic material. More preferably, the hydrophobic material is selected from the group of glycerine fatty acid esters, vegetable oils and their derivatives, higher fatty acids, their metal salts and other material with similar properties. It will be appreciated by art-skilled workers that the release rate of the active agent in the second component is controlled by the amount of the hydrophobic material presented in the formulation in an amount within the range of from about 2-80% (w/w) and/or in the proportion to the active substance from (1 : 10) to (10: 1).
- the second component is conveniently not granulated, but can, also, be in the form of granules in which the hydrophobic material (e.g.
- the main role of the hydrophobic (second) component of the system is to control the penetration rate of the gastrointestinal fluid into the dosage form and, thereby, to control the release of the drug available in untreated form (in the second component).
- the hydrophobic component also, indirectly, controls the release of the drug available inside the granules.
- the release of the drug available in the granules (first component) is controlled by both the water-insoluble, but water-permeable polymer and, also, the hydrophobic material in the second component. Therefore, if the system (the dosage form) fails accidentally (e.g. as a result of food intake) or naturally (due to gastrointestinal motility), the risk of dose dumping is minimised because the first component would not release the drug due to control by the water-insoluble, but water- permeable polymer.
- the pharmaceutically active agent of the second component is the same as that of the first component.
- the pharmaceutically active agent may also comprise a mixture of agents. Having the same active pharmaceutical agent in the first and second components affords a formulation in which part of the active agent is available for substantially immediate release (depending on the quantity of hydrophobic material added), and part of the active agent will be released over a prolonged period of time.
- formulations in which the first and second components comprise different pharmaceutically active agents are also contemplated and are by no means excluded.
- the first component may be prepared by combining the pharmaceutically active agent with a polymeric substance that is insoluble in water, but permeable to water.
- the release rate of the active agent from the first component can be controlled by adjusting the amount of the polymer, depending on the physico-chemical characteristics of the active agent.
- standard pharmaceutical excipients can be used to obtain granules with appropriate compressibility for tabletting.
- the first component is in granular form and two components are in the admixture.
- the first component may also contain one or more pharmaceutically acceptable excipients.
- suitable excipients include (but are not limited to) lactose and/or microcrystalline cellulose, croscarmellose sodium, starch and/or starch derivatives. Such excipients can also be used to enhance the permeability of water to the granules, and, consequently, enhance the release rate of the drug if required. Lactose and microcrystalline cellulose are examples of suitable filler excipients.
- the second component of the system contains the pharmaceutically active agent available for substantially immediate release.
- the release process can be controlled by the amount of hydrophobic material in the second component.
- the second component may also contain one or more pharmaceutically acceptable excipients and/or tabletting aids.
- Fillers, glidants, lubricants and mixtures thereof may also be provided in the second component.
- Non-limiting examples include calcium hydrogen phosphate and hydrogenated vegetable oil NF, Type I. Conveniently, these may be mixed with talc and magnesium stearate.
- the dosage form is a tablet or capsule.
- the dosage formulation is an oral dosage formulation.
- sustained release profiles afforded by a dosage formulation of the invention make it suitable to be adapted to many different types of dosage forms.
- Non-limiting examples of other dosage forms contemplated include suppositories and subcutaneous implants.
- Controlled release oral dosage formulations of the invention may be in the form of tablet compressed from a blend of the two components, and, also:
- hard (e.g. gelatin) capsules containing both granules (the first component) or mixture of the second component and one or more tablets.
- the granules are mixed with the second component which comprises: the active agent, a hydrophobic material (preferably a lipid or lipidic material such as fatty acids or their esters) and some tabletting materials (e.g. antiadherents, glidants, lubricants), and then compressed into tablets.
- a hydrophobic material preferably a lipid or lipidic material such as fatty acids or their esters
- some tabletting materials e.g. antiadherents, glidants, lubricants
- a film coating may optionally be added to the dosage formulation.
- the coating layer can be either non-functional (for example to give an elegant appearance, identification or colour) or functional, such as enteric coating, or to incorporate the active in the coating layer for rapid release for immediate action (instant release).
- the film coating may conveniently comprise one or more film formers, plasticisers, colouring agents, and mixture thereof.
- the water insoluble polymeric substances suitable for granulation and/or control of the release of the drug from the granules can be chosen from, but not restricted to, the range of methacrylic acid copolymers, such as Eudragit RS or Eudragit RL (either in the form of a powder or aqueous suspension or a combination of both forms), Eudragit NE 40D or Eudragit NE 30D, or a combination of both polymers in appropriate amounts and forms (powder/suspension).
- methacrylic acid copolymers such as Eudragit RS or Eudragit RL (either in the form of a powder or aqueous suspension or a combination of both forms), Eudragit NE 40D or Eudragit NE 30D, or a combination of both polymers in appropriate amounts and forms (powder/suspension).
- the pharmaceutically active agent is generally an agent required to be administered by sustained release.
- examples of such agents include agents with toxicity in high doses and agents to be administered over an extended period of time.
- the controlled release formulation of the present invention may contain active agent(s) from a variety of therapeutical ly active groups, such as, for example, ace-inhibitors, alkaloids, antacids, analgesics, anabolic agents, anti-anginal drugs, anti-allergy agents, anti-arrhytmia agents, antiasthmatics, antibiotics, anticholesterlolemics, anticonvulsants, anticoagulants, anti-emetics, antihistamines, antihypertensives, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), steroidal anti-inflammatory drugs, central nervous system (CNS) stimulators, CNS depressants, antimigraine agents,contraceptives, cough suppresants, deodorants, dermatological agents, diuretics, fungicides, gastro-intestinal agents, vitamins , minerals polypeptides, prostaglandins, respiratory stimulans, uterine relaxants, and many others already known, as well as the new
- the active ingredient contained in the second component is preferably in untreated form as a pure substance.
- the active ingredient contained in the second component is either in untreated form as a pure substance, or, optionally, in the form of solid dispersion in a carrier.
- the substance may be blended with pharmaceutical excipients suitable for further processing (tabletting or capsuling).
- the carrier of the solid dispersion may be selected from a wide range of polymers (e.g. various types of polyethylene glycols) or other standard pharmaceutical excipients, such as, for example, polyvinyl pyrrolidone (povidones, Kollidon VA 64) and others.
- polymers e.g. various types of polyethylene glycols
- other standard pharmaceutical excipients such as, for example, polyvinyl pyrrolidone (povidones, Kollidon VA 64) and others.
- solubility enhancers such as substances capable of creating a microenvironment with optimum pH solubilization of the drug, can be included in the second component.
- the qualities and quantities of excipients can be determined on the basis of in-vitro experiments according to the desired release profile(s) of the drug(s).
- the hydrophobic material used to control the release process from the second component is preferably chosen from a range of lipids or lipidic material, such as hydrogenated vegetable oils, pharmaceutical fats, fatty acids, glycerides, waxes and others.
- adjusting the proportion of the active agent in the first and second components can control the release of the active agent.
- Example 1- Controlling the release rate by varying the amount of water-insoluble (but water-permeable) polymeric material (Figure 1)
- Granules were prepared from a mixture of diclofenac sodium with microcrystalline cellulose, lactose and Eudragit RS as a binder, used in powder form and/or in the form of an aqueous suspension. Wet granules were dried in a fluid-bed dryer and then milled through a 20 mesh (0.8 mm) screen to obtain appropriate size distribution of the granules suitable for compressing.
- Granules and the remaining part of the active drug, diclofenac sodium, lipid component, calcium hydrogenphosphate, hydrogenated vegetable oil NF Type I and talc were screened through a 20 mesh sieve and tumble mixed for 5 minutes.
- Magnesium stearate, screened through a 30 mesh (0.6 mm) sieve was then added to the final blend and mixed for another 5 minutes.
- the final blend was compressed into tablets. Tablets were coated with the aqueous suspension of methylhydroxypropylcellulose, polysorbatum, sodium lauryl sulfate, talc and pigments such as titanium dioxide as well as iron oxides red and yellow.
- Example 2- Controlling the release rate by varying the amount of lipid/lipidic component as an additional retarding agent (Figure 2)
- Granules and tablets were prepared in the same way as described in the Example 1.
- Example 3- Controlling the release rate by varying both the amount of water-insoluble (but water-permeable) polymeric material and lipid/lipidic component ( Figure 3)
- Granules were prepared from a mixture of diclofenac sodium with or without microcrystalline cellulose and lactose, with Eudragit RS as a binder, used in powder form and/or in the form of an aqueous suspension. Wet granules were dried in a fluid-bed dryer and then milled through a 20 mesh (0.8 mm) screen to obtain appropriate size distribution of the granules suitable for compressing.
- Granules and the remaining part of the active drug, diclofenac sodium, lipid component, with or without calcium hydrogenphosphate and hydrogenated vegetable oil NF Type I, and with talc were screened through a 20 mesh sieve and tumble mixed for 5 minutes.
- Magnesium stearate, screened through a 30 mesh (0.6 mm) sieve was then added to the final blend and mixed for another 5 minutes.
- the final blend was compressed into tablets.
- Tablets containing part of torasemide in granulated form using a methacrylic acid copolymer as the binder, and the remaining torasemide in non-granulated form mixed with a lipid are included in the binder.
- Example 5- Controlling the release rate by varying the amount of water-insoluble (but water-permeable) polymeric material ( Figure 5)
- Granules were prepared from a mixture of torasemide with Eudragit RS as a binder, used in powder form and/or in the form of an aqueous suspension. Wet granules were dried in a fluid-bed dryer and then milled through a 20 mesh (0.8 mm) screen to obtain appropriate size distribution of the granules suitable for compressing.
- Granules and the remaining part of the active drug, torasemide, lipid component and talc were screened through a 20 mesh sieve and tumble mixed for 5 minutes.
- Magnesium stearate, screened through a 30 mesh (0.6 mm) sieve was then added to the final blend and mixed for another 5 minutes. The final blend was compressed into tablets.
- Example 6- Controlling the release rate by varying the amount of lipid/lipidic component as an additional retarding agent ( Figure 6)
- Granules and tablets were prepared in the same way as described in the Example 5.
- Example 7 Controlling the release rate by varying both the amount of water-insoluble (but water-permeable) polymeric material and lipid/lipidic component ( Figure 7)
- Example 8 Controlling the release rate by varying the amount of water-insoluble (but water-permeable) polymeric material ( Figure 8)
- Granules were prepared from a mixture of ranitidine in the form of ranitidine hydrochloride with Eudragit RS as a binder, used in powder form and/or in the form of an aqueous suspension. Wet granules were dried in a fluid-bed dryer and then milled through a 20 mesh (0.8 mm) screen to obtain appropriate size distribution of the granules suitable for compressing.
- ranitidine in the form of ranitidine hydrochloride, lipid component, hydrogenated vegetable oil NF, Type I and talc were screened through a 20 mesh sieve and tumble mixed for 5 minutes.
- Magnesium stearate, screened through a 30 mesh (0.6 mm) sieve was then added to the final blend and mixed for another 5 minutes. The final blend was compressed into tablets.
- Example 9 Controlling the release rate by varying the amount of lipid/lipidic component as an additional retarding agent ( Figure 9)
- Granules and tablets were prepared in the same way as described in the Example 8.
- Example 10- Controlling the release rate by varying both the amount of water-insoluble (but water-permeable) polymeric material and lipid/lipidic component (Figure 10)
- Granules and tablets were prepared in the same way as described in the Example 8. It is envisaged that the dosage forms of the present invention will enable controlled delivery of a range of drugs to be provided in a way that maximises therapeutic benefit and patient compliance, while minimising side effects of the drug.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003572553A JP2006507216A (en) | 2002-02-11 | 2002-03-27 | Sustained release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
YU70704A RS70704A (en) | 2002-02-11 | 2002-03-27 | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
HU0500097A HUP0500097A3 (en) | 2002-02-11 | 2002-03-27 | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
CA002476050A CA2476050A1 (en) | 2002-02-11 | 2002-03-27 | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
SK330-2004A SK3302004A3 (en) | 2002-02-11 | 2002-03-27 | Controlled release solid formulations - novel drug delivery system with reduced risk of dose dumping |
EP02708556A EP1474112A1 (en) | 2002-02-11 | 2002-03-27 | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
EEP200400110A EE200400110A (en) | 2002-02-11 | 2002-03-27 | Controlled / prolonged release solid dosage form as a novel drug delivery system with reduced risk of dose dumping |
US10/504,014 US20050118266A1 (en) | 2002-02-11 | 2002-03-27 | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
IS7386A IS7386A (en) | 2002-02-11 | 2004-08-05 | Fixed continuous / controlled release formulation as a new dosing system with reduced dose release risk |
NO20043818A NO20043818L (en) | 2002-02-11 | 2004-09-10 | Fixed controlled release formulation as a new drug delivery system with reduced risk of overdose |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20020124A HRP20020124A2 (en) | 2002-02-11 | 2002-02-11 | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
HRP20020124A | 2002-02-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003074033A1 true WO2003074033A1 (en) | 2003-09-12 |
WO2003074033A8 WO2003074033A8 (en) | 2004-07-08 |
Family
ID=27772919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HR2002/000018 WO2003074033A1 (en) | 2002-02-11 | 2002-03-27 | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050118266A1 (en) |
EP (1) | EP1474112A1 (en) |
JP (1) | JP2006507216A (en) |
AU (1) | AU2004205184A1 (en) |
BG (1) | BG108870A (en) |
CA (1) | CA2476050A1 (en) |
CZ (1) | CZ2004931A3 (en) |
EE (1) | EE200400110A (en) |
HR (1) | HRP20020124A2 (en) |
HU (1) | HUP0500097A3 (en) |
IS (1) | IS7386A (en) |
NO (1) | NO20043818L (en) |
PL (1) | PL371787A1 (en) |
RS (1) | RS70704A (en) |
RU (1) | RU2004127237A (en) |
SK (1) | SK3302004A3 (en) |
WO (1) | WO2003074033A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1732517A1 (en) | 2004-03-25 | 2006-12-20 | Ferrer Internacional, S.A. | Prolonged-release compositions comprising torasemide and a matrix-forming polymer |
WO2008049657A2 (en) * | 2006-10-26 | 2008-05-02 | Evonik Röhm Gmbh | Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release |
WO2011036114A1 (en) * | 2009-09-25 | 2011-03-31 | Novartis Ag | Oral pharmaceutical composition comprising diclofenac |
US9827199B2 (en) | 2012-09-03 | 2017-11-28 | Daiichi Sankyo Company, Limited | Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
JP2008525313A (en) * | 2004-12-27 | 2008-07-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Anti-dementia drug stabilization method |
US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
WO2009042722A1 (en) | 2007-09-25 | 2009-04-02 | Neosync, Inc. | Systems and methods for depression treatment using neuro-eeg synchronization therapy |
US8926490B2 (en) * | 2008-09-24 | 2015-01-06 | Neosync, Inc. | Systems and methods for depression treatment using neuro-EEG synchronization therapy |
US8465408B2 (en) * | 2009-08-06 | 2013-06-18 | Neosync, Inc. | Systems and methods for modulating the electrical activity of a brain using neuro-EEG synchronization therapy |
WO2011059986A1 (en) | 2009-11-12 | 2011-05-19 | Neosync, Inc. | Systems and methods for neuro-eeg synchronization therapy |
WO2011102506A1 (en) | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | Sustained-release solid preparation for oral use |
WO2011102504A1 (en) | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | Sustained-release solid preparation for oral use |
AU2011224350B2 (en) * | 2010-03-09 | 2015-07-02 | Alkermes Pharma Ireland Limited | Alcohol resistant enteric pharmaceutical compositions |
WO2014060857A1 (en) * | 2012-10-19 | 2014-04-24 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
US10588576B2 (en) | 2014-08-15 | 2020-03-17 | Neosync, Inc. | Methods and device for determining a valid intrinsic frequency |
JP1602547S (en) | 2017-01-17 | 2018-04-23 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2103927A (en) * | 1981-08-22 | 1983-03-02 | Council Scient Ind Res | Sub-dermal sustained-release pharmaceutical implants |
EP0196700A1 (en) * | 1985-03-13 | 1986-10-08 | Rijksuniversiteit Te Groningen | Devices for the controlled release of active substances, as well as process for the preparation thereof |
EP0368247A2 (en) * | 1988-11-08 | 1990-05-16 | Takeda Chemical Industries, Ltd. | Controlled release preparations |
EP0383967A1 (en) * | 1989-02-17 | 1990-08-29 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
US4980170A (en) * | 1988-06-30 | 1990-12-25 | Klinge Pharma Gmbh | Pharmaceutical formulation as well as a process for its preparation |
EP0468436A1 (en) * | 1990-07-25 | 1992-01-29 | Ss Pharmaceutical Co., Ltd. | Sustained-release tablet |
WO1994008576A1 (en) * | 1992-10-16 | 1994-04-28 | Glaxo Group Limited | Taste-masking compositions of ranitidine |
WO1997039744A1 (en) * | 1996-04-23 | 1997-10-30 | Janssen Pharmaceutica N.V. | Immediate release ph-independent solid dosage form of cisapride |
WO1997044014A1 (en) * | 1996-05-20 | 1997-11-27 | Janssen Pharmaceutica N.V. | Antifungal compositions with improved bioavailability |
US5958452A (en) * | 1994-11-04 | 1999-09-28 | Euro-Celtique, S.A. | Extruded orally administrable opioid formulations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6183778B1 (en) * | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
DE19524753A1 (en) * | 1995-07-07 | 1997-01-23 | Lohmann Therapie Syst Lts | Layered tablet for the controlled release of active ingredients |
US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
-
2002
- 2002-02-11 HR HR20020124A patent/HRP20020124A2/en not_active Application Discontinuation
- 2002-03-27 PL PL02371787A patent/PL371787A1/en unknown
- 2002-03-27 US US10/504,014 patent/US20050118266A1/en not_active Abandoned
- 2002-03-27 CZ CZ2004931A patent/CZ2004931A3/en unknown
- 2002-03-27 CA CA002476050A patent/CA2476050A1/en not_active Abandoned
- 2002-03-27 WO PCT/HR2002/000018 patent/WO2003074033A1/en active Application Filing
- 2002-03-27 HU HU0500097A patent/HUP0500097A3/en unknown
- 2002-03-27 EE EEP200400110A patent/EE200400110A/en unknown
- 2002-03-27 SK SK330-2004A patent/SK3302004A3/en not_active Application Discontinuation
- 2002-03-27 RU RU2004127237/15A patent/RU2004127237A/en not_active Application Discontinuation
- 2002-03-27 JP JP2003572553A patent/JP2006507216A/en active Pending
- 2002-03-27 RS YU70704A patent/RS70704A/en unknown
- 2002-03-27 EP EP02708556A patent/EP1474112A1/en not_active Withdrawn
-
2004
- 2004-08-05 IS IS7386A patent/IS7386A/en unknown
- 2004-08-23 AU AU2004205184A patent/AU2004205184A1/en not_active Abandoned
- 2004-09-10 NO NO20043818A patent/NO20043818L/en not_active Application Discontinuation
- 2004-09-10 BG BG108870A patent/BG108870A/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2103927A (en) * | 1981-08-22 | 1983-03-02 | Council Scient Ind Res | Sub-dermal sustained-release pharmaceutical implants |
EP0196700A1 (en) * | 1985-03-13 | 1986-10-08 | Rijksuniversiteit Te Groningen | Devices for the controlled release of active substances, as well as process for the preparation thereof |
US4980170A (en) * | 1988-06-30 | 1990-12-25 | Klinge Pharma Gmbh | Pharmaceutical formulation as well as a process for its preparation |
EP0368247A2 (en) * | 1988-11-08 | 1990-05-16 | Takeda Chemical Industries, Ltd. | Controlled release preparations |
EP0383967A1 (en) * | 1989-02-17 | 1990-08-29 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
EP0468436A1 (en) * | 1990-07-25 | 1992-01-29 | Ss Pharmaceutical Co., Ltd. | Sustained-release tablet |
WO1994008576A1 (en) * | 1992-10-16 | 1994-04-28 | Glaxo Group Limited | Taste-masking compositions of ranitidine |
US5958452A (en) * | 1994-11-04 | 1999-09-28 | Euro-Celtique, S.A. | Extruded orally administrable opioid formulations |
WO1997039744A1 (en) * | 1996-04-23 | 1997-10-30 | Janssen Pharmaceutica N.V. | Immediate release ph-independent solid dosage form of cisapride |
WO1997044014A1 (en) * | 1996-05-20 | 1997-11-27 | Janssen Pharmaceutica N.V. | Antifungal compositions with improved bioavailability |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1732517A1 (en) | 2004-03-25 | 2006-12-20 | Ferrer Internacional, S.A. | Prolonged-release compositions comprising torasemide and a matrix-forming polymer |
JP2007530510A (en) * | 2004-03-25 | 2007-11-01 | フエルレル インターナショナル,ソシエダッド アノニマ | Prolonged-release composition comprising toracemide and a matrix-forming polymer |
EP1732517B1 (en) * | 2004-03-25 | 2017-05-03 | Ferrer Internacional, S.A. | Prolonged-release compositions comprising torasemide and a matrix-forming polymer |
WO2008049657A2 (en) * | 2006-10-26 | 2008-05-02 | Evonik Röhm Gmbh | Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release |
WO2008049657A3 (en) * | 2006-10-26 | 2008-10-30 | Evonik Roehm Gmbh | Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release |
WO2011036114A1 (en) * | 2009-09-25 | 2011-03-31 | Novartis Ag | Oral pharmaceutical composition comprising diclofenac |
US9827199B2 (en) | 2012-09-03 | 2017-11-28 | Daiichi Sankyo Company, Limited | Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
US20050118266A1 (en) | 2005-06-02 |
HUP0500097A2 (en) | 2005-07-28 |
HRP20020124A2 (en) | 2003-10-31 |
EP1474112A1 (en) | 2004-11-10 |
JP2006507216A (en) | 2006-03-02 |
BG108870A (en) | 2005-12-30 |
RU2004127237A (en) | 2005-04-20 |
SK3302004A3 (en) | 2005-04-01 |
WO2003074033A8 (en) | 2004-07-08 |
IS7386A (en) | 2004-08-05 |
EE200400110A (en) | 2004-10-15 |
AU2004205184A1 (en) | 2005-03-03 |
HUP0500097A3 (en) | 2008-04-28 |
RS70704A (en) | 2006-10-27 |
NO20043818L (en) | 2004-09-30 |
CA2476050A1 (en) | 2003-09-12 |
PL371787A1 (en) | 2005-06-27 |
CZ2004931A3 (en) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7374781B2 (en) | Sustained release formulations containing acetaminophen and tramadol | |
US20050118266A1 (en) | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping | |
AU741361B2 (en) | Modified release matrix formulation of cefaclor and cephalexin | |
KR101094231B1 (en) | Sustained release solid formulations and methods of manufacturing the same | |
CN113573712A (en) | Pharmaceutical composition of nilotinib | |
CZ73196A3 (en) | Novel balls for controlled release and pharmaceutical preparation in which said balls are contained | |
JP2001278813A (en) | Oral administration form having delayed active substance release and high mechanical stability, medicine having the same administration form and use of such administration form | |
JPH061716A (en) | Medical prescription having long-term releasability of active ingredient | |
EP1499300A1 (en) | Pharmaceutical formulations with improved bioavailability | |
TW201503913A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
JP2014196334A (en) | Sustained release pharmaceutical composition containing quetiapine | |
CN108201534A (en) | A kind of Rui Kapabu takes orally sustained and controlled release medicament composition and application thereof | |
CN110035751A (en) | A kind of Wei Lipani sustained and controlled release medicament composition and application thereof | |
WO2007146068A2 (en) | Controlled release alfuzosin hydrochloride formulation | |
CA2781826A1 (en) | Controlled release pharmaceutical compositions of galantamine | |
KR101002583B1 (en) | Methods of manufacturing sustained release solid formulations | |
EP1556014A1 (en) | Sustained release compositions containing alfuzosin | |
AU2014295098B2 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
EP2010158B1 (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
WO2006067601A1 (en) | Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation | |
RU2810927C2 (en) | Pharmaceutical compositions with cdc7 inhibitor | |
US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
JP2014101332A (en) | Orally disintegrating sustained release tablet containing ambroxol hydrochloride | |
KR20200077911A (en) | A pharmaceutical composition of sustained-release comprising zaltoprofen | |
WO2013111147A1 (en) | Extended release compositions of nevirapine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-707/04 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT BA BG BR BY CA CH CN CO CR CZ DE DK DZ EC EE ES FI GB GE GH HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MK MN MX NO NZ PH PL PT RO RU SE SG SI SK TJ TM TN TR TZ UA US UZ YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 37/2003 UNDER (72, 75) REPLACE "KHAN, ZAHIRUL, M., I." BY "KHAN, M. ZAHIRUL, I." |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163289 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2476050 Country of ref document: CA Ref document number: 2003572553 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3302004 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002708556 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2004-931 Country of ref document: CZ Ref document number: 535127 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 108870 Country of ref document: BG Ref document number: 10887002 Country of ref document: BG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004127237 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002708556 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10504014 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV2004-931 Country of ref document: CZ |